Varicella Vaccine attenuated

Varicella Vaccine, also known as the Chickenpox Vaccine, is an attenuated live virus vaccine that helps protect against the highly contagious chickenpox illness. Chickenpox is a common childhood disease caused by the varicella-zoster virus (VZV), characterized by an itchy rash, fever, and tiredness. The vaccine is typically administered in two doses, the first at 12-15 months of age and the second at 4-6 years old.
The Varicella Vaccine contains a weakened form of the virus that stimulates the immune system to develop immunity against the disease without causing illness. The vaccine is safe and effective in preventing chickenpox, reducing the severity of symptoms, and minimizing the risk of complications such as bacterial infections, pneumonia, and neurological issues.
In addition to protecting children, the Varicella Vaccine also helps reduce the spread of chickenpox among those who are not immunized. The vaccine has been shown to have a high efficacy rate of approximately 90%, and its widespread use has led to a significant decrease in the number of chickenpox cases and associated hospitalizations.
The Varicella Vaccine is a vital component of childhood immunization schedules and plays a crucial role in preventing chickenpox and its complications, promoting overall public health and well-being.